-
Exclusive: DelMar Pharma CEO Sheds Light On Glioblastoma, And How Its Drug Could Help Sen. John McCain
Friday, July 21, 2017 - 9:09am | 915Read More...Glioblastoma is a rare type of brain cancer thrust into the spotlight after it was reported Sen. John McCain has been diagnosed with the very aggressive disease. Glioblastoma affects 15,000–17,000 new patients in the United States every year, and treatment options haven’t changed much...
-
Do Analysts See A Path Forward For Ophthotech's Fovista?
Friday, March 24, 2017 - 2:35pm | 452Read More...After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing...
-
Imprimis CEO Talks Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success
Thursday, December 1, 2016 - 12:03pm | 510Read More...Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) is a San Diego-based small-cap pharmaceutical company that specializes in the ophthalmology space. The company is coming off an impressive 81 percent year-over-year increase in revenues in its most recent quarter and clocked nearly a 20 percent...
-
Here's Why Novocure Is Having A Huge Day
Monday, November 23, 2015 - 1:19pm | 400Read More...Shares of Novocure Ltd (NASDAQ: NVCR) surged higher on Monday by more than 10 percent. Novocure announced new Phase 3 data, in which patients who received the company's Optune in combination with bevacizumab at first recurrence lived "significantly longer" than those who just received bevacizumab...
-
Did OXiGENE Win a Crucial Battle In the Fight Against Cancer?
Wednesday, March 12, 2014 - 3:52pm | 224Read More...On Tuesday, OXiGENE (NASDAQ: OXGN) announced that a Phase 2 trial of its ZYBRESTAT ovarian cancer drug has “met its primary endpoint of a statistically significant increase in progress-free survival” of patients with ovarian cancer. Patients given a combination of ZYBRESTAT with an already...
-
FDA Probably Going to Let Breast Cancer Sufferers Die
Tuesday, June 28, 2011 - 4:28pm | 441Read More...What is the point of having a government regulatory body if we can't even agree that women with breast cancer should get every tool in the toolbox to try and save their life? The drug in question is Avastin, and for some women, it's been the literal difference between life and death. Patricia...
